An interventional study of Transcranial Magnetic Stimulation (TMS) and Emotion Regulation Skills Training in Borderline Personality Disorder (BPD), sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Borderline Personality Disorder with a site in United States — 15 open to participants now, 17 under way, none of them phase 3. Borderline Personality Disorder · United States.
Among the 81 studies in Borderline Personality Disorder with a site in United States, this one is the 63rd largest by planned enrollment of the 71 interventional ones that give a count, is one of 3 that started in 2026, is one of 39 with no phase, reaches primary completion later than 11 of the 16 other live ones, and was the 80th registered.
279 studies on the registry are indexed under Borderline Personality Disorder; 70 are open to participants now.
Browse Borderline Personality Disorder studies →15 of the 81 studies in Borderline Personality Disorder with a site in United States are open now. Recruiting first, the newest first:
Mclean Hospital · Sites in United States
Ages 18+
Yale University · Sites in United States
Ages 18–60
University of California, Los Angeles · Sites in United States
Ages 18–65
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–55
Matthew Southward, PhD · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Borderline Personality Disorder studies recruiting now, 18 (37%) set no upper age limit and 30 (61%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.
This study: 22 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 19 · Phase 3 6 · Phase 4 6
First in 1997; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 70 across 222 interventional studies indexed under Borderline Personality Disorder.
Median enrollment 56 across the 71 interventional studies, 48 across the 7 observational. Of the 57 that completed or were terminated, 22 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 81 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
Massachusetts General Hospital has 3 studies filed under Borderline Personality Disorder — fewer than ten, so there is no comparison to draw.
7 of the studies in Borderline Personality Disorder with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04870255Stanford UniversityTreatment of Acute Mood Depressive Episode in Borderline Personality Disorder With rTMS | 2026-12 |
| NCT05651295Matthew Southward, PhDA Precision Medicine Approach to Target Engagement for Emotion Regulation | 2026-12-31 |
| NCT06683014Yale UniversityMDMA in Borderline Personality Disorder | 2027-06 |
| NCT07460947Mclean HospitalA Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder | 2027-06 |
| NCT06772831Icahn School of Medicine at Mount SinaiCognitive Reappraisal Training for Borderline Personality (BPD) | 2027-07-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 81 studies in Borderline Personality Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Impaired emotion regulation is a core feature of borderline personality disorder (BPD) and a known driver of functional impairment, interpersonal difficulties, self-harm, and suicidality. Emotion regulation refers to the ways in which people influence and control which emotions they have, when they have them, and how they experience and express them. Effective emotion regulation is a precursor to success in a range of adaptive processes including decision making, impulse control, communication and social interaction, work performance and productivity, and goal achievement, with subsequent positive effects on mood stability and well-being.
Front-line behavioral approaches to teach effective emotion regulation skills in BPD (e.g. DBT) have been moderately successful, but outcomes are limited by high dropout rates due to lengthy treatment protocols and pre-existing deficits in the neurocircuitry supporting engagement in emotion regulation, with poorer outcomes in individuals with more severe emotion dysregulation.
In this pilot feasibility trial, we aim to test an approach to improving emotion dysregulation in BPD by combining neuromodulation using transcranial magnetic stimulation (TMS), to improve functioning of emotion regulation related neurocircuitry, with an intensive, brief emotion regulation skills training protocol. Through this combined approach, we hypothesize increased gains in emotion regulation ability, decreased treatment dropout rates, and improved positive outcomes in patients with BPD.
Emotion dysregulation has long been established as the core characteristic feature of borderline personality disorder (BPD). Large scale mediation analyses have identified emotion dysregulation as a key driver of the most impairing effects of this disorder, including interpersonal difficulties, self-harm and suicidality.1 Further, emotion dysregulation has been found to have a transactional relationship with overall BPD symptoms, with significant bi-directional relationships between severity of emotion regulation difficulties and severity of BPD symptoms, suggesting emotion dysregulation goes hand in hand with BPD. Thus, effectively improving emotion regulation (ER) skills is crucial to ameliorating the devastating experience and deleterious effects of this disorder.
For the past decade, we have been studying emotion regulation both on the behavioral level and on the level of neurocircuit function. These studies have primarily focused on bipolar disorder (BD) rather than BPD. However, there is significant overlap in the experience and negative effects of emotion dysregulation between the two disorders, and they are often diagnostically indistinguishable. The specific focus on emotion dysregulation rather than symptoms means these studies are likely relevant to both disorders. This is supported by findings in the BPD literature that overlap with our prior studies. Key takeaways from these studies thus far are: 1) Response to behavior-based ER skills training alone (e.g. CBT) is limited by impaired baseline functioning of ER neurocircuitry, with weaker functional connectivity predicting poorer outcomes. Similar findings have been shown in BPD, with weaker baseline functioning of ER neurocircuit regions predicting poorer outcomes to DBT specifically and psychotherapy in general. 2) Functional connectivity deficits between key nodes in ER neurocircuitry (anterior insula, inferior parietal lobule) distinguish BD from healthy controls, and is significantly related to severity of emotion dysregulation. Similar findings have been shown in studies of BPD patients, which found similar weak functional connectivity between anterior insula and ER circuit regions including the IPL, significantly associated with ER deficits. 3) Modulation of this ER circuit pathway using transcranial magnetic stimulation (TMS) improves ER functional connectivity and behavioral performance on a laboratory task. We have been able to demonstrate both increased AI-IPL functional connectivity and improved performance on an ER behavioral task following IPL stimulation in patients with BD. Given the existing overlap in findings related to ER in both disorders, we hypothesize similar results to be found in patients with BPD.
Thus, taken together, behavioral ER skills training may be a viable approach to improving emotion dysregulation, but is limited by intrinsic ER neurocircuit function. Directly modulating ER neurocircuitry improves ER neurocircuit function and performance on a laboratory analogue of ER behavior, but the effects on real-world ER skills is unknown. Importantly, focusing on ER related neurocircuit function in isolation from the behavioral and psychological processes involved in ER, and vice versa, may not be sufficient to provide relief to those individuals struggling with severe emotion dysregulation, as there is an important bidirectional relationship between these neurocircuit and behavioral components. It remains an open question, therefore, whether improving neurocircuit function supporting emotion regulation while simultaneously addressing the psychological and behavioral processes driving emotion dysregulation can provide synergistic relief to the devastating impact of emotion dysregulation.
Existing approaches to improving ER in BPD Dialectical Behavioral Therapy (DBT) has long been the gold standard for treating individuals with BPD. However, whereas DBT can be a powerful and effective intervention, outcomes are hampered by the extensive length of treatment (one year for a full course of DBT), leading to treatment dropout rates as high as 58% in outpatient settings. This has led to the development of brief versions of DBT (e.g. 12 sessions, 6-month protocols) focused on teaching mindfulness and emotion regulation skills. However, response to these briefer versions have been discouraging, with over 50% of patients showing no clinically significant decrease in symptoms, and sometimes further deterioration. Further, evidence suggests individuals with BPD who show greater baseline deficits in emotion regulation neurocircuit function benefit less from treatment. This suggests two great needs for the field of BPD treatment: 1) briefer efficacious behavioral protocols focused on emotion regulation skills training, and 2) interventions that can strengthen ER neurocircuit function.
The current proposal seeks to address both of these needs, by collecting early Phase 1 pilot data on a combined approach using neuromodulation to strengthen ER neurocircuitry combined with an intensive, brief behavioral approach to teaching ER skills. If we can show this approach is feasible and acceptable, and preliminary evidence for efficacy, data from this trial will provide crucial preliminary evidence to support funding for a larger, randomized controlled clinical trial
What is emotion regulation? Emotion regulation has been operationally defined as the process by which individuals influence and modulate which emotions they have, when they have them, and how they experience and express them. Adaptive emotion regulation requires the detection of emotion salience (e.g. threat, reward), the evaluation of the match between the salience signal and ongoing situational demands, and the modulation of responses accordingly (e.g. attention, appraisal, behavior). Modulating attention between implicit salience signals and explicit ongoing situational, goal-directed demands is a key early component to successful emotion regulation supporting both cognitive change and response modulation.
Emotion regulation can be thought of as a broad construct that provides the scaffolding for many complex cognitive and behavioral processes necessary for adaptive functioning, including decision making, impulse control, and social/interpersonal interactions. Effective emotion regulation has been shown to lead to diminished susceptibility to cognitive and psychological biases in decision making, leading to more adaptive risk assessment (greater or lower risky decisions dependent upon context). A recent review demonstrated that the neurocircuitry involved in effective decision-making overlaps with the neurocircuitry of emotion regulation, suggesting effective decision making inherently relies upon ER-related processes (such as conscious attention shifting, explicit weighting of competing appraisals, dampening or increasing emotion arousal). Studies examining the relationship between impulsivity and emotion regulation suggest impulsivity may be the result of failure to effectively regulate responses to salience signaling and is better accounted for in BPD as a consequence of emotion dysregulation rather than as a separate construct. Studies of interpersonal effectiveness and social communication have demonstrated a significant relationship between adaptive emotion regulation skills and effective communication and social bonding. Studies in BPD show emotion dysregulation mediates responses to a social rejection task, with higher levels of emotion dysregulation associated with higher perceived threat and distress during the task. Thus, improving emotion regulation skills in BPD may not only ameliorate the negative effects of emotion dysregulation, but also provides support for improvement in a range of difficulties inherent in the disorder.
Rationale for targeting IPL to improve ER in BD. The current proposal extends our ongoing work using iTBS to the IPL to improve emotion regulation. Existing studies of healthy individuals implicate distributed cortical neurocircuitry supporting emotion regulation via modulation of limbic structures. Of these regions, the IPL plays a critical role in integrating salience signals with higher-order cognitive functions and support the modulation of attention in service of ongoing goal-directed demands. The IPL forms the intersection of the ventral attention network (VAN), the dorsal attention network (DAN), and the frontoparietal control network (FPC), crucial for voluntarily re-orienting attention and behavior in response to relevant interoceptive stimuli in order to align with ongoing goal-directed needs. Thus, the IPL is uniquely situated as a key integrative hub within the ER neurocircuitry facilitating adaptive ER through the modulation of regulatory control via both ventral and dorsal attention networks and limbic structures. We propose a key mechanism leading to ER deficits is weakened engagement of IPL-AI functional circuitry, resulting in reduced ability to regulate attention and subsequent behavior to direct attention away from irrelevant salient cues, disrupting early attentional processes crucial to the engagement of adaptive ER.
Evidence for Efficacy of ER Skills Training with the UP The ER skills training in this proposal is adapted from the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP), an evidence-based, emotion regulation protocol. The UP was developed based upon evolutionary emotion science and modeled after Gross's temporal process model of ER. Core modules are designed to teach skills encompassing the specific adaptive ER processes of attention deployment, cognitive change, and response modulation. The UP consists of 6 core modules: (1) psychoeducation on the nature and function of emotions; (2) present-focused awareness training to facilitate objective awareness and identification of maladaptive conditioned emotion responses; (3) interoceptive awareness training to identify the contribution of physiological responses to maladaptive thoughts and behaviors; (4) automatic thoughts and cognitive reappraisal skills to identify and modify maladaptive automatic appraisals; (5) the identification and modification of maladaptive emotion driven behaviors; and (6) emotion exposures to promote extinction of conditioned responses. The UP has demonstrated efficacy in improving ER skills in a range of transdiagnostic samples including BPD. We previously tested the UP plus pharmacotherapy treatment-as-usual (TAU) with TAU alone in the treatment of BD and comorbid anxiety and demonstrated significantly greater effects in the UP+TAU group on ER skills, and this further predicted improvements in anxiety and mood symptoms. A recent study in patients with unipolar depression and comorbid generalized anxiety disorder combined transcranial direct current stimulation (tDCS) with the UP. Results from this study found significantly greater improvement in ER skills, greater endorsement of cognitive reappraisal, greater response inhibition, and greater working memory accuracy and response relative to the UP alone or waitlist control (all p's\<.001). The effects held at 3-month follow-up. These results suggest combining UP ER skills training with neuromodulation may confer an advantage over skills training alone.
In this pilot trial, we aim to test the feasibility and acceptability of ER skills training delivered adjunctive to aiTBS in individuals with BPD with regard to recruitment, retention, UP module completion, patient satisfaction with treatment and endorsement of side effects or discomfort (e.g. fatigue). In addition, we aim to collect pilot data on the preliminary efficacy of combined ER skills training (UP) and accelerated TMS (aiTBS). Results from this trial will provide pilot data towards a future randomized controlled clinical trial of this approach.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combined accelerated TMS and emotion regulation skills training
Device: Transcranial Magnetic Stimulation (TMS) · Behavioral: Emotion Regulation Skills Training
accelerated (multi-session) intermittent theta-burst transcranial magnetic stimulation (aiTBS)
Also known as: TMS, iTBS, aiTBS
Cognitive behavioral therapy based emotion regulation skills training using the Unified Protocol
Also known as: Unified Protocol, UP, cognitive behavioral therapy, CBT
Client Satisfaction Questionnaire (CSQ)
Self-report measure of participant satisfaction with the interventions
Time frame: From baseline to end of acute treatment at 8 weeks
UP Module Completion Rate
Measure of percentage of emotion skills training modules completed
Time frame: From enrollment to the end of treatment at 8 weeks
Session Completion Rate
Measure of percentage of study visits attended
Time frame: From baseline to end of acute treatment at 8 weeks
Emotion Regulation Skills Questionnaire (ERSQ)
Self report measure of adaptive emotion regulation skills
Time frame: Baseline through acute treatment end at 8 weeks
Borderline Evaluation of Severity Over Time (BEST)
Self-report measure of severity of BPD symptoms
Time frame: Baseline through acute treatment end at 8 weeks
Affective Multi-Source Interference Task (MSIT-IAPS)
Computer-based behavioral task of emotion regulation
Time frame: Baseline through acute treatment end at 8 weeks
Delay-Discounting Task (DDT)
Computer-based behavioral task of decision making
Time frame: Baseline through acute treatment end at 8 weeks
Cyberball Social Rejection Task (CSRT)
Computer-based behavioral task of social rejection
Time frame: Baseline through acute treatment end at 8 weeks
IPL-aIns Functional connectivity changes
Changes in correlated BOLD time-series between inferior parietal lobule (IPL, TMS target) and anterior insula (aIns)
Time frame: Baseline through post-TMS at 3 weeks
Plan to share: Yes — Participants can indicate permission to share de-identified data with other researchers during consenting. Allowable de-identified data will be shared with other researchers by contacting PI (Ellard) and following the establishment of appropriate data sharing use agreements (DUA).
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.
Of 106 non-industry interventional studies with no phase under Borderline Personality Disorder, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 54. This study's planned 12 months is below that.
Counting every sponsor, half of 108 studies reached it within 35 months; a quarter within 24 and three quarters within 53.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 26, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Borderline Personality Disorder →
Massachusetts General Hospital →